Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT04169698

Alendronate Versus Denosumab in Kidney Transplant Patients

Evaluation of the Efficacy and Tolerability of Alendronate Versus Denosumab in Kidney Transplant Patients With Reduced Bone Mineral Density

Sponsor: Ain Shams University

Conditions Osteoporosis, Osteopenia Renal Transplant Recipient

Interventions Alendronate 70Mg Tab Denosumab 60 mg/ml [Prolia]

Updated 5 times since 2019 Last updated: Nov 11, 2021 Started: Oct 17, 2019 Primary completion: May 1, 2021 Completion: May 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Osteoporosis, Osteopenia and Renal Transplant Recipient, this trial is completed. The trial is conducted by Ain Shams University and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed
Jan 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ain Shams University
Nahda University

Data source: Ain Shams University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt